{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:09:40Z","timestamp":1793426980599,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.radonc.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T20:27:10Z","timestamp":1587587230000},"page":"157-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":651,"special_numbering":"C","title":["Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document"],"prefix":"10.1016","volume":"148","author":[{"given":"Yolande","family":"Lievens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-9071","authenticated-orcid":false,"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-0008","authenticated-orcid":false,"given":"Morten","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kindts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"M\u00e9ndez Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-7621","authenticated-orcid":false,"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.04.003_b0005","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/JTO.0b013e3182208e58","article-title":"A 10-year single-center experience on 708 lung metastasectomies: the evidence of the \u201cinternational registry of lung metastases\u201d","volume":"6","author":"Casiraghi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2020.04.003_b0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jamcollsurg.2007.04.039","article-title":"Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases","volume":"205","author":"Miller","year":"2007","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.radonc.2020.04.003_b0020","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligo-metastatic non-small cell lung cancer \u2013 a consensus report","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0035","unstructured":"Lewis D, Gardner E. \u201cDo the trials\u201d: Caution urged in ASTRO Presidential Symposium on routine use of SABR as curative in metastatic cancer. 2019."},{"key":"10.1016\/j.radonc.2020.04.003_b0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0045","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0060","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.04.003_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2020.04.003_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review","author":"Giaj-Levra","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101892","article-title":"Evolution of treatment strategies for oligometastatic NSCLC patients \u2013 A systematic review of the literature","volume":"80","author":"Schanne","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2020.04.003_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.radonc.2020.04.003_b0085","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.prro.2017.10.008","article-title":"Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study","volume":"8","author":"Nguyen","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.07.018","article-title":"Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma","volume":"16","author":"Barata","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0095","article-title":"Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial","author":"Bowden","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.04.003_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clon.2015.08.011","article-title":"Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients","volume":"28","author":"De Rose","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2020.04.003_b0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10585-019-09976-z","article-title":"Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions","volume":"36","author":"Dell'Acqua","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2020.04.003_b0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00000658-197711000-00014","article-title":"Metastatic carcinomas from occult primary tumors. A study of 254 patients","volume":"186","author":"Didolkar","year":"1977","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2020.04.003_b0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12885-016-2379-x","article-title":"Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer","volume":"16","author":"Fleckenstein","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0130","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00432-018-2692-7","article-title":"Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation","volume":"144","author":"Franzese","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.radonc.2018.10.024","article-title":"Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy","volume":"133","author":"Franzese","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.juro.2018.08.049","article-title":"Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma","volume":"201","author":"Franzese","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2020.04.003_b0145","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1002\/cam4.1707","article-title":"The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer","volume":"7","author":"Franzese","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2020.04.003_b0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13014-018-1048-4","article-title":"Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease","volume":"13","author":"Gerum","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0155","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT","author":"Horner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0165","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0170","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0175","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.21873\/anticanres.11621","article-title":"Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer","volume":"37","author":"Jingu","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2020.04.003_b0180","first-page":"e211","article-title":"Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy","volume":"16","author":"Kinj","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2017.08.006","article-title":"Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases","volume":"112","author":"Kwint","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0195","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.04.003_b0200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00259-018-4159-0","article-title":"Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer","volume":"46","author":"Lepinoy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2020.04.003_b0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?","volume":"124","author":"Merino Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0215","first-page":"43","article-title":"Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease","volume":"5","author":"Mihai","year":"2017","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.radonc.2020.04.003_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.04.003_b0225","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1002\/cam4.2366","article-title":"Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer","volume":"8","author":"Ouyang","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2020.04.003_b0230","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a Cooperative Study of the Korean Radiation Oncology Group (KROG 14\u201311)","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2020.04.003_b0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.04.003_b0240","doi-asserted-by":"crossref","first-page":"100708","DOI":"10.18632\/oncotarget.20022","article-title":"Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis","volume":"8","author":"Santini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2020.04.003_b0245","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0250","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/COC.0000000000000419","article-title":"Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach","volume":"41","author":"Tran","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jrr\/rrv063","article-title":"Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study","volume":"57","author":"Aoki","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2020.04.003_b0270","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/hpb.12044","article-title":"Multicentre results of stereotactic body radiotherapy for secondary liver tumours","volume":"15","author":"Berber","year":"2013","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.radonc.2020.04.003_b0275","article-title":"Stereotactic body radiation therapy for pulmonary oligometastases arising from non-lung primaries in patients without extrapulmonary disease","volume":"10","author":"Dohopolski","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2020.04.003_b0280","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.21037\/apm.2017.03.08","article-title":"Palliative efficacy and local control of conventional radiotherapy for lung metastases","volume":"6","author":"Fleming","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.radonc.2020.04.003_b0285","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00432-017-2373-y","article-title":"Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours","volume":"143","author":"Franceschini","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0290","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/07357907.2016.1197235","article-title":"Role of stereotactic body radiation therapy with volumetric-modulated arcs and high-intensity photon beams for the treatment of abdomino-pelvic lymph-node metastases","volume":"34","author":"Franzese","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2020.04.003_b0295","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/0284186X.2017.1378432","article-title":"Acute toxicity of the bowel after stereotactic robotic radiotherapy for abdominopelvic oligometastases","volume":"57","author":"Frelinghuysen","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0300","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.prro.2015.10.011","article-title":"Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases","volume":"6","author":"Goodman","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.04.003_b0310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","article-title":"Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer","volume":"37","author":"Jereczek-Fossa","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease \u2013 Influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0320","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2018.02.016","article-title":"Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy","volume":"127","author":"Klement","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0325","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1080\/0284186X.2017.1346383","article-title":"Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis","volume":"56","author":"Lancia","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0330","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10585-018-9922-x","article-title":"Locoregional control and survival after lymph node SBRT in oligometastatic disease","volume":"35","author":"Loi","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2020.04.003_b0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12032-018-1190-8","article-title":"Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study","volume":"35","author":"Mazzola","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0340","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1748-717X-9-91","article-title":"Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments","volume":"9","author":"Navarria","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0345","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3109\/0284186X.2012.681698","article-title":"Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung","volume":"51","author":"Oh","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2018.06.018","article-title":"30 Gy single dose stereotactic body radiation therapy (SBRT): report on outcome in a large series of patients with lung oligometastatic disease","volume":"122","author":"Osti","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0355","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cllc.2013.06.006","article-title":"Clinical outcomes of single dose stereotactic radiotherapy for lung metastases","volume":"14","author":"Osti","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0360","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.prro.2013.05.006","article-title":"Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases","volume":"4","author":"Owen","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","article-title":"Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group \u201cstereotactic radiotherapy\u201d","volume":"97","author":"Rieber","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0370","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/0284186X.2018.1521986","article-title":"Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy","volume":"58","author":"Sharma","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0375","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clon.2015.01.004","article-title":"Comparison of single-fraction and multi-fraction stereotactic radiotherapy for patients with 18f-fluorodeoxyglucose positron emission tomography-staged pulmonary oligometastases","volume":"27","author":"Siva","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2020.04.003_b0380","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.clon.2014.06.018","article-title":"Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience","volume":"26","author":"Thibault","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2020.04.003_b0385","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.18632\/oncotarget.7636","article-title":"Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2020.04.003_b0390","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/jjco\/hyw047","article-title":"Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases","volume":"46","author":"Yamashita","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0395","article-title":"Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time","author":"Dhondt","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2020.04.003_b0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050141","article-title":"Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs","volume":"7","author":"Lussier","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2020.04.003_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028650","article-title":"MicroRNA expression characterizes oligometastasis(es)","volume":"6","author":"Lussier","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2020.04.003_b0410","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2020.04.003_b0415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2018.04.022","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fonc.2019.00111","article-title":"Hypofractionated stereotactic radiotherapy for non-breast or prostate cancer oligometastases: a tail of survival beyond 10 years","volume":"9","author":"Aujla","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0430","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0435","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2018.08.027","article-title":"Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer","volume":"103","author":"Sutera","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.04.003_b0440","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3747\/co.26.4116","article-title":"Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer","volume":"26","author":"Laurie","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0445","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and oligo-recurrence: the new era of cancer therapy","volume":"40","author":"Niibe","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0450","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state \u2013 separating truth from wishful thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0455","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2020.04.003_b0460","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0465","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0470","unstructured":"Agency EM. Guideline on the evaluation of anticancer medicinal products in man. 2017"},{"key":"10.1016\/j.radonc.2020.04.003_b0475","unstructured":"FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. 2018."},{"key":"10.1016\/j.radonc.2020.04.003_b0480","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(18)30917-3","article-title":"Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective","volume":"20","author":"Lievens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0490","first-page":"304","article-title":"CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases","volume":"63","author":"Napieralska","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.radonc.2020.04.003_b0495","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.clon.2017.02.004","article-title":"Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases","volume":"29","author":"Chang","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2020.04.003_b0500","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/07357907.2015.1019678","article-title":"Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose","volume":"33","author":"Seo","year":"2015","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2020.04.003_b0505","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group","volume":"91","author":"deSouza","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.04.003_b0510","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.04.003_b0515","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1080\/0284186X.2017.1348622","article-title":"Access to innovative radiotherapy: how to make it happen from an economic perspective?","volume":"56","author":"Lievens","year":"2017","journal-title":"Acta Oncol"},{"issue":"1048","key":"10.1016\/j.radonc.2020.04.003_bib516","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140712","article-title":"Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease","volume":"88","author":"Bhattacharya","year":"2015","journal-title":"Br J Radiol."},{"key":"10.1016\/j.radonc.2020.04.003_bib517","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2019.01.001","article-title":"The METABANK score: A clinical tool to predict survival after\u00a0stereotactic\u00a0radiotherapy\u00a0for\u00a0oligometastatic\u00a0disease","volume":"133","author":"Van den Begin","year":"2019","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.radonc.2020.04.003_bib518","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40520-018-0937-6","article-title":"Oligometastatic cancer in elderly patients: the \u201cblitzkrieg\u201d radiotherapy approach","volume":"31","author":"Lancia","year":"2019","journal-title":"Aging\u00a0Clin Exp Res."},{"issue":"3","key":"10.1016\/j.radonc.2020.04.003_bib519","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.radonc.2020.04.003_bib520","article-title":"Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multi-arm Phase I trial","volume":"91","author":"Deodato","year":"2019","journal-title":"Br J Radiol."},{"issue":"4","key":"10.1016\/j.radonc.2020.04.003_bib521","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2009.12.038","article-title":"Predictors of local control aftersingle-dose stereotactic\u00a0image-guided intensity-modulated radiotherapy for extracranial metastases","volume":"79","author":"Greco","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"14","key":"10.1016\/j.radonc.2020.04.003_bib522","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.radonc.2020.04.003_bib523","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdt537","article-title":"Stereotactic radiotherapy for oligometastatic\u00a0cancer: a prognostic model for survival","volume":"25","author":"de Vin","year":"2014","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1016\/j.radonc.2020.04.003_bib524","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2015.04.004","article-title":"Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy","volume":"92","author":"Binkley","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"10.1016\/j.radonc.2020.04.003_bib525","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following\u00a0stereotactic\u00a0body\u00a0radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol."},{"issue":"2","key":"10.1016\/j.radonc.2020.04.003_bib526","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","article-title":"Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer","volume":"95","author":"Muldermans","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"10.1016\/j.radonc.2020.04.003_bib527","first-page":"304","article-title":"Cyberknife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases","volume":"63","author":"Napieralska","year":"2016","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.radonc.2020.04.003_bib528","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive Factors for Response and Survival in a Cohort of\u00a0Oligometastatic\u00a0Patients Treated With Stereotactic Body Radiation Therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.radonc.2020.04.003_bib529","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10585-010-9325-0","article-title":"Oligometastases confined one organ from colorectal cancer treated by SBRT","volume":"27","author":"Kang","year":"2010","journal-title":"Clin Exp Metastasis."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:11:51Z","timestamp":1759122711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020301845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":117,"alternative-id":["S0167814020301845"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}